The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback